Röchling Expanding Its Medical Division
Röchling Group has invested 35 million euros ($42.6 million) to expand and scale up medical production capacity at its site in Neuhaus am Rennweg, Germany.
The German group said April 20 that the investment, one of the group’s largest, involved the addition of a new production building at the site as part of growth strategy of its medical division.
The expansion will increase capacity "significantly’"at Röchling Medical Neuhaus GmbH, improving the market position of the company which specializes in manufacturing primary packaging for the pharmaceutical and diagnostics industries.
The Röchling Group launched the medical division in 2016, bolstering its two existing divisions: industrial and automotive.
Röchling Medical said its “intensive marketing” had led to major projects, which, it said, necessitated the expansion of production capacity for co-extrusion blow molding.
Looking for chemical products? Let suppliers reach out to you!
2026-07-05
-
Life Sciences Industry Overview
The coverage spans the global life sciences industry across pharmaceuticals and food & nutrition, tracking the shift from lowest-cost sourcing to supply continuity, quality, and risk management, along with product trends and the growing edge of differentiated, globally capable players.Published in: June.2026
Trade Alert
Delivering the latest product trends and industry news straight to your inbox.
(We'll never share your email address with a third-party.)
Related News
-
China丨Xinjiang Weinongbao Biotechnology to build a green agrochemical formulation facility
-
US丨Vive Crop Protection closes funding round, accelerating its precision chemistry platform
-
Dow: Considering big investment after China-US trade situation is clear
-
Biocon Weighs Merger of Biocon Biologics to Unlock Value
-
Novo Nordisk Sounds the Alarm: Growth Headwinds Loom Over Global Operations in 2026
-
Sun Pharma’s Utreglutide Shows Promising Weight Loss and Liver Fat Reduction
-
Pharma’s Tightrope in 2026: Safety, Competition and the Future of Obesity Treatment Innovation
-
Small Pharma Firms Under Threat as Regulator Tightens Quality Norms
-
Merck Nears Acquisition of Cidara to Strengthen Flu Prevention Arsenal
-
FDA Orders Removal of “Suicidality Warning”: Are Weight-Loss Blockbusters Finally Cleared—or Is Regulators Giving the Market a Reality Check?
Recommend Reading
-
U.S. API Dependence Turns Pharmaceutical Ingredients Into a National Security Issue
-
Pharma Tariff Risk Pushes Global Drugmakers to Rebuild U.S. Supply Chains
-
FDA Names Veteran Oncology Regulator Pazdur as Director of Drug Review Center
-
India Strengthens Drug Approval Oversight with Expanded CDSCO Powers
-
Pfizer Sues Metsera and Novo Nordisk Over Rival Obesity Drug Strategy
-
He Spent 40 Years at Nestlé—Then Was “Cleared Out” Days After Becoming CEO: This Isn’t a Scandal, It’s Capital’s Coldest Face
-
5%–10% Is Just the Surface: Behind Dow’s Greater China Price Letter Lies a Global Repricing of Silicones
-
“Changing the Captain at Sea”: Hempel’s CEO Departs to Run a Ferry Giant—This Isn’t a Resignation Notice, It’s an Industry Stress Map
-
This week, the market price of pure benzene in China rose slightly (8.4-8.8)
-
This Week's PVC Prices Show Narrow Fluctuations (8.4-8.8) in China